4(phenyl-piperazinyl-methyl) benzamide derivatives and their...

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C514S252130, C514S253010, C514S253090, C514S253100, C514S253110, C514S255040, C544S396000, C544S360000, C544S366000, C544S367000, C544S370000, C544S372000, C544S374000

Reexamination Certificate

active

10533764

ABSTRACT:
Compounds of general formula:[Chemical formula should be inserted here. Please see paper copy] wherein R1, R2, and R3are as defined in the specification, as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain

REFERENCES:
patent: 3940386 (1976-02-01), Szabo et al.
patent: 5574159 (1996-11-01), Chang et al.
patent: 5681830 (1997-10-01), Chang et al.
patent: 5807858 (1998-09-01), Chang et al.
patent: 5854249 (1998-12-01), Chang et al.
patent: 6130222 (2000-10-01), Roberts et al.
patent: 6680318 (2004-01-01), Brown et al.
patent: 6680321 (2004-01-01), Roberts et al.
patent: 6696447 (2004-02-01), Brown et al.
patent: 6784181 (2004-08-01), Brown et al.
patent: 2431178 (1975-01-01), None
patent: 2900810 (1980-07-01), None
patent: 0133323 (1985-02-01), None
patent: 0166302 (1986-01-01), None
patent: 0283310 (1988-09-01), None
patent: 0289227 (1988-11-01), None
patent: 0624584 (1998-08-01), None
patent: 2696744 (1994-04-01), None
patent: 2076403 (1981-12-01), None
patent: 2210366 (1989-06-01), None
patent: 7-138230 (1995-05-01), None
patent: WO 86/04584 (1986-08-01), None
patent: WO 91/07967 (1991-06-01), None
patent: WO 93/15062 (1992-02-01), None
patent: WO 92/04338 (1992-03-01), None
patent: WO 93/15062 (1993-08-01), None
patent: WO 95/04051 (1995-02-01), None
patent: WO 97/23466 (1997-07-01), None
patent: WO 98/28270 (1998-07-01), None
patent: WO 98/28275 (1998-07-01), None
patent: WO 99/33806 (1999-07-01), None
patent: WO 01/45637 (2001-06-01), None
patent: WO 01/46174 (2001-06-01), None
patent: WO 01/74805 (2001-10-01), None
patent: WO 02/094794 (2002-11-01), None
patent: WO 03/029215 (2003-04-01), None
patent: WO 2004/041800 (2004-05-01), None
patent: WO 2004/041801 (2004-05-01), None
patent: WO 2005/066148 (2005-07-01), None
Saitoch, A.; Potential Anxiolytic and Antidepressant-Like Activities of SNC80, a Selective delta-Opioid Agonist, in Behavioral Models in Rodents; J. Pharmacol. Sci.; 2004; 95; 374-380.
Filliol, D.; Nature Genetics; 2000; 25; 195-200.
U.S. Appl. No. 10/533,654, filed May 4, 2005, Brown et al.
U.S. Appl. No. 10/533,744, filed May 4, 2005, Brown et al.
U.S. Appl. No. 10/714,447, filed Nov. 17, 2003, Roberts et al.
U.S. Appl. No. 10/477,642, filed Nov. 13, 2003, Brown et al.
Bilsky et al., “SNC 80, A Selective, Nonpeptidic and Systemically Active Opioid Delta Agonist,” J. Pharmacol. Experi. Ther. 273:359-366 (1995).
Takemori et al., “Selective Natrexone-Drived Opioid Receptor Antagonists,” Annu. Rev. Pharmacol. Toxicol. 32:239-269 (1992).
Bilsky et al., “Characterization of Enantiomers of (+) BW373U86 and Related Compounds: Highly Selective Non-Peptidic Delta Opioid Agonists,” Reg. Peptides 54:25-26 (1994).
Calderon et al., “Probes for Narcotic Receptor Mediated Phenomena. 19. Synthesis of . . . Opioid Receptor Agonist,” J. Med. Chem. 37:2125-2128 (1994).
Calderon et al., “Probes for Narcotic Receptor Mediated Phenomena. 23. Synthesis . . . Opioid Receptor Ligands,” J. Med. Chem. 40:695-704 (1997).
Chang et al., “A Novel, Potent and Selective Nonpeptidic Delta Opioid Receptor Agonist BW373U86,” J. Pharmacol. Exper. Therap. 267:852-857 (1993).
Katrizky et al., “Benzotriazole-Mediated Arylalkylation and Heteroarylalkylation,” Chem. Soc. Rev. 23:363-373 (1994).
Kingsbury et al., “Synthesis of Structural Analogs of Leukotriene B and their Receptor Binding Activity,” J. Med. Chem. 36:3308-3320 (1993).
Lopez et al., “Exploring the Structure-Activity Relationships . . . Opioid Receptor Nonpeptide Agonist Ligand,” J. Med. Chem. 42:5359-5368 (1999).
Plobeck et al., “New Diarylmethylpiperazines as Potent and Selective Nonpeptidic Opioid Receptor Agonists with Increased In Vitro Metabolic Stability,” J. Med. Chem. 43:3878-3894 (2000).
Suggs et al., “Facile Synthesis fo 8-Substituted Quinolines,” J. Org. Chem., 45:1514-1515 (1980).
Zhang et al., “Probes for Narcotic Receptor Mediated Phenomena. 26. Synthesis . . . Opioid Receptor Ligands,” J. Med. Chem. 42:5455-5463 (1999).
English Abstract for Reference B16 on PTO/SB/08A, p. 4.
English Abstract for Reference B17 on PTO/SB/08A, p. 4.
English Abstract for Reference B18 on PTO/SB/08A, p. 4.
English Abstract for Reference B19 on PTO/SB/08A, p. 4.
Burkey et al., “The Efficacy of Delta-Opioid Receptor-Selective Drugs,” Medline Abstract for Life Sci. 62:1531-1536 (1998).
Nagase et al., “The Pharmacological Profile of Delta Opioid Receptor Ligands, (+) and (−) TAN-67 on Pain Modulation,” Medline Abstract for Life Sci. 68:2227-2231 (2001).
Green, “Protective Groups in Organic Synthesis,” pp. 267-268 and 331 (1981).
Abstract for HU 217619. A corresponding English language PCT application is cited as Reference B1 listed on PTO/SB/08A, p. 1.
Abstract for HU 215487. A corresponding English language PCT application is cited as reference B2 on PTO/SB/08A, p. 1.
Nortey et al., “Piperazinyl Benzamidines: Synthesis and Affinity for the Delta Opioid Receptor,” Bioorganic & Medicinal Chemistry Letters, vol. 11, pp. 1741-1743 (2001).
Snyder et al., “Historical Review: Opioid Receptors,” Trends in Pharmacological Sciences, vol. 24, pp. 198-205 (2003).
Filliol, D. et al., “Mice deficient for δ- and μ-opioid receptors exhibit opposing alterations of emotional responses,” Nature Genetics, vol. 25, pp. 195-200, Jun. 2000.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

4(phenyl-piperazinyl-methyl) benzamide derivatives and their... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 4(phenyl-piperazinyl-methyl) benzamide derivatives and their..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 4(phenyl-piperazinyl-methyl) benzamide derivatives and their... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3797075

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.